Ropes & Gray advised Sanofi in a strategic equity investment in Torino, Italy-based Resalis Therapeutics. Resalis plans to use the proceeds to advance development of its lead candidate RES-010 through a Phase 2 clinical trial for a therapy targeting the molecular pathways underlying obesity and metabolic diseases. The transaction was announced on October 28.
The Ropes & Gray team included life sciences licensing associates Daniel Freshman, Amanda White and Ryan Kramer and life sciences licensing partner Abigail Gregor.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.